Sustained Virologic Response Rates from a Randomized Trial of HCV Genotype-1 Subjects Treated with Either Cons (Hepatitis C Infection)

Sustained Virologic Response Rates from a Randomized Trial of HCV Genotype-1 Subjects Treated with Either Cons
HIV and Hepatitis.com - Valeant will pay InterMune $113.5 million in cash upon closing, and subsequent milestone payments of up to approximately $22.5 million. Valeant also will acquire an estimated $6.5 million in inventory from InterMune. that greater than 50% of HCV genotype 1 individuals treated with the

Consensus IFN+ IFN Gamma-1b in African-American Peg Nonresponders
National AIDS Treatment Advocacy Project - Blatt2 1The New Jersey School of Dentistry and Medicine, Newark, NJ 2InterMune, Inc., IFN-_-2 + RBV who had log10 reduction in HCV RNA (nonresponders). Therapy was switched to a combination of was defined as having undetectable HCV RNA 24 weeks after the last